American Society for Clinical Pharmacology and Therapeutics, Clinical Pharmacology & Therapeutics, 4(97), p. 380-394
DOI: 10.1002/cpt.76
Full text: Unavailable
The development of CNS drugs is associated with high failure rates. It is postulated that too much focus has been put on BBB permeability and too little on understanding BBB transport, which is the main limiting factor in drug delivery to the brain. An integrated approach to collecting, understanding, and handling pharmacokinetic-pharmacodynamic information from early discovery stages to the clinic is therefore recommended in order to improve translation to human drug treatment.